Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma
Status:
Terminated
Trial end date:
2019-10-16
Target enrollment:
Participant gender:
Summary
The primary objective of this single arm phase 2 trial is to assess the response rate
[complete response (CR) + partial response (PR)] of sequential therapy of pembrolizumab
followed by HD IL-2 in subjects with stage IV malignant melanoma. Response assessment will be
performed after pembrolizumab therapy, and response reassessment will be performed after HD
IL-2 therapy using revised RECIST 1.1.
Phase:
Phase 2
Details
Lead Sponsor:
Ralph Hauke
Collaborators:
Nebraska Cancer Specialists; Midwest Cancer Center-Legacy Prometheus Laboratories